Plumbagin Triggers STING Pathway Activation to Suppress Non-Small Cell Lung Cancer Progression

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Non-small cell lung cancer (NSCLC) is a major global health concern.
• Plumbagin (PLBG), a natural naphthoquinone, has demonstrated anti-cancer properties.
• The precise mechanisms of PLBG's anti-tumor effects in NSCLC require further elucidation.

Purpose of the Study:

• To investigate the anti-cancer mechanisms of Plumbagin (PLBG) in non-small cell lung cancer (NSCLC).
• To explore the role of reactive oxygen species (ROS) and the STING pathway in PLBG-induced anti-tumor activity.

Main Methods:

• Cell proliferation and apoptosis assays were performed on NSCLC cells treated with PLBG.
• Reactive oxygen species (ROS) levels and mitochondrial function were assessed.
• RNA sequencing was employed to identify differentially expressed genes.
• The STING pathway activation and chemokine upregulation were analyzed.

Main Results:

• PLBG significantly inhibited NSCLC cell proliferation and induced apoptosis.
• PLBG elevated intracellular and mitochondrial ROS, leading to mitochondrial dysfunction.
• N-acetylcysteine (NAC) reversed PLBG-induced apoptosis, confirming ROS involvement.
• PLBG activated the STING pathway and upregulated chemokines (CXCL10, CXCL9, CCL5).
• STING inhibition attenuated PLBG-induced apoptosis, highlighting STING's critical role.

Conclusions:

• PLBG exhibits potent anti-NSCLC effects by inducing ROS-mediated apoptosis and activating the STING pathway.
• PLBG upregulates key chemokines, contributing to its anti-tumor activity.
• PLBG demonstrates potential as a therapeutic agent for NSCLC.